This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 315| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2434 | AZI1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.46 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2435 | LOC654342 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.58 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2436 | TPR | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.86 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2437 | CENPI | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.69 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2438 | CBX1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.68 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2439 | CCHCR1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.57 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2440 | STMN1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.52 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2441 | AUP1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.33 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2442 | IQGAP3 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.24 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2443 | NFYA | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.41 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2444 | TH1L | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.54 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2445 | SLC39A4 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 4.42 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2446 | MEIS2 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.28 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2447 | CIT | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.26 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2448 | KIAA0286 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.99 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2449 | FAM48A | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.83 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2450 | CCNF | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.72) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2451 | IPO9 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.64 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2452 | MTA3 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.61 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2453 | CSRP2BP | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.57 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2454 | XPO1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.44 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2455 | C14orf93 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.43 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2456 | C5orf13 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.56 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2457 | EHMT2 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.80 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2458 | STX6 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.24 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2459 | MCM8 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.34 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2460 | MEF2B | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.49) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2461 | FAM34A, NARS, HSPC152, GRP58, GBA, PVRL2, RPS17, LAMR1, GNB1, AHNAK, GRCC10, SPTAN1, CTSC, NSE1, COP1, NDRG1, HSPA5, SPARC, ATP5J2, KIAA0663, CD24, NUDT3, CANX | RNAs | Human | Downregulated in among all types HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 16391793 |
| 2462 | SMYD3, FABP1, Ceruloplasmin, A2M, IGFBP, PPAP2B, SHMT, PHLDA1, APOA1, SOCS2, ETS2, MT2A, CYP39A1, HAMP, CYP2C9, SLC22A1, PLG, GAMT, FGG, KRT8, IFITM1, C1R, FGB, FGA, GC (vitamin D binding protein), SERPINA3, WAC, | RNAs | Human | Upregulated in among all types HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 16391793 |
| 2463 | CLU | RNAs | Human | Upregulated in metastatic HCC than primary HCC | Diagnostic and Prognostic | Primary and metastatic HCC | p < 0.001 | Cell line and Tissue | 16247463 |
| 2464 | EGR3, MFAP3, EST, MMP9, PDCD4, EST, FLJ37853, ARHE, MAD2L1, NMNAT2, FLJ22016, SND1, MIDORI, FLJ36229, MGST2, CTPS2, OASL, HK2, EEF2, Taxilin, NT5C, CLNS1A, UNC5B, TSC, TNFSF6, KIAA1691, S100A10, ATP6V1D, ASB4, AGR2, KIAA0205, JJAZ1, LOC285859, KIAA0157, PPA2, eIF3k, SGKL, BLMH, ERG-1, BRCA2, PPP2R2A | RNAs | Human | Differentially expressed (14 Upregulated and 49 Downregulated) in treatment responder v/s non-responders | Predictive | treatment responder v/s non-responders | p < 0.01 | Tissue | 15447987 |
| 2465 | GPC3, CAP2, UBD, MT1F, PTDSS1, RDS, ID1, NNMT, AA127809, PRRG2, ACAA1, SLC22A1, BE779749, FACL2, PRLR, C8orf4, C6, CCNH, AK022114, CBFA2T3, EPAS1, API5, SULT2A1, PGM1, C9, NQO1, C1R, PMS1, DSCR1, PPP1R2, GOT1, ZNF6, AI831040, GCLC, MYOZ2, HMGCL, UBE4A, SERPING1, PLG, ADFP, RODH, MARCO, C9orf59, BG71 | RNAs | Human | Differentially expressed (GPC3, CAP2, UBD Upregulated and rest 41 are Downregulated) in tumor v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.001 | Tissue | 15607117 |
| 2466 | MT1B, MT1E, MT1L, CP, ABCA1, CACNB3, PROS1, CPB2, SERPINC1, LACI, MDK, C6, C9, CD5L, GPR126, IL1RAP, DYRK3, PCDH17, TACSTD1, UAP1, C20orf3, CFL2, FLJ12666, KIAA0843, MRC1, NAT2, MYO1B, SIPL, SRD5A2, USP1, | RNAs | Human | Differentially expressed (PCDH17, MDK, TACSTD1 Upregulated and rest 27 are Downregulated) in High-risk individuals with cirrhosis v/s patients with HCC | Prognostic | High-risk individuals with cirrhosis v/s patients with HCC | p < 0.0003 | Tissue | 14768006 |
| 2472 | AURKB | Protein and RNAs | Human | Upregulated in HCC tissues in association with aggressive recurrence v/s non-recurrence | Prognostic | Aggressive recurrence HCC v/s non-recurrence HCC | p < 0.001 | Tissue | 18311747 |
| 2483 | MYO1D, EST, PDGF-B, LOC113246, SPTAN1, MGC19556, IL6R, PRPSAP1, PDCD6IP, AHNAK, BCL2L11, GPAA1, c-fos, SLC11A2, LOC51235, PRPF8, CD36L1, KIAA1055, HNRPDL, NDRG1, NARS, PABPC4, RDBP, CALM2, PDCD6, C1R, ALB, MT1G, CED-6, AMACR, A2M, FGG, SUPV3L1, PHLDA1, NBP, HAMP, HCS, KIAA0635, ECHS1, SHMT1, NNMT, A | RNAs | Human | Differentially expressed between HCC and non-tumor liver tissue | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 14642619 |
| 2484 | SOX6, ITIH4, HDGF, SKIP1, RBP4, LOC92033, UGT2B7, FABP1, GATM, UQCRC1, UK114, CP, PBEF, KAL1, CES2, GPX4, UGT1A4, RCL, PABPC1, EST, FGA, RARRES2, SLC22A, SRP14, FLJ14294, cyclin, CA2, CLDN1, FTL, FLJ10004, CYP3A5, ARHGEF12, TDO2, NDUFB2, TEGT, SPR, PCK2, MGC13114, EST, MTHFS, F2, FLJ22313, C9orf5, H | RNAs | Human | Differentially expressed between HCC and normal tissues | Diagnostic | HCC v/s normal | p < 0.01 | Tissue | 14642619 |
| 2485 | IGFBP3, c-fos, p21 | RNAs | Human | Differentially expressed between HCC and non-tumor liver tissue | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 14642619 |
| 2486 | p53, cyclin D1 | RNAs | Human | Differentially expressed between HCC and normal tissues | Diagnostic | HCC v/s normal | p < 0.01 | Tissue | 14642619 |
| 2499 | SEMA3F, DDX17, TNFAIP, PDGFRA, VIM, LAPTM5, CCND2, HLADRA, MEF2C, Staf50, SGK, REL, | RNAs | Human | Diffrenetially Expressed between recurrent and non-recurrent HCC | Prognostic | Early intrahepatic recurrence and non-recurrence HCC | p < 0.05 | Tissue | 12648972 |
| 2500 | RYBP, ATP1B3, TMC, ZNF567, GPR108, CD19, SPINK1, CDC2L6, RSRC1, METAP, GPC3, SNHG11, RY1, CRELD2, GLUL, SERPINB1, TRMT6, UNC13D, E4F1--E4F, SLC22A2, CNIH4, TK1, MAFB, PPP1CB, DNTTIP2, ARID4B, SMARCC2, PRO1386, TRIOBP, VARS, ITGA5, TERF1, PURA, TUBA1B, SNRPE, RRAGD, VWF, GLRX3, ILF2, | RNAs | Human | Upregulated in HCV related HCC than normal control (With 3-fold change) | Diagnostic | HCV related HCC v/s normal control | p < 0.01 | Tissue | 19821982 |
| 2501 | NMNAT3, OASL, TMPRSS3, MFSD7, AEBP1, UBD, S100A4, C1orf151, CRIP1, ASCC3, ZNF271, ANXA4, NMI, UBE2L6, B2 M, HLA-F, PSMB9, TAP1, PSME2, IFI16, IFI27, ARHGAP9, RABGAP1L, TNK1, DEF6, BTN3A3, RPS6KA1, CD24, PARP10, APOL3, STAT, ANKRD10, CKB, H2AFZ, PSMB9, RARRES3, RGS10, TUBB, NOL3, CD7, | RNAs | Human | Upregulated in HCV related non-HCC than normal control (With 3-fold change) | Diagnostic | HCV related non-HCC v/s normal control | p < 0.01 | Tissue | 19821982 |
| 2502 | CAPG, OCC-1, EED, RPLP0, RPLP0P2, AP1S2, RRAGD, PFDN4, CCDC104, C7orf28B, PSIP1, LPCAT1, FSCN3, RAB24, ZNF446, SEC11B, ZNF586, SCNM1, SF3A1, RUFY1, TRIM55, GOLGA4, GPATCH4, THOP1, TUBB2C, PHLDB3, FAM104A, FASTK, EIF2AK4, ZFP41, PRKRIP1, DSTN, PHIP, NUCKS1, TNRC8, CCDC132, EPRS, HIST1H4C, CDCA8, | RNAs | Human | Upregulated in HCV related HCC than HCV related non-HCC (With 3-fold change) | Diagnostic | HCV related HCC v/s HCV related non-HCC | p < 0.01 | Tissue | 19821982 |
| 2503 | Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Tr | RNAs | Human | Diffrenetially expressed in HCC v/s non-tumor | Diagnostic | HCC v/s non-tumor | p < 0.01 | Tissue | 11973655 |
| 2504 | CDC28 protein kinase2, CDC27HS protein, Integrin beta 4, Desmoplakin 1/2, Procollagen C proteinase, platelet derived growth factor, cytidine deaminase, aminoacyalse1, Betaine homocysteine S-methyltransferase, methylenetetrahydrofolate dehydrogease, metalloproteinase inhibitor1, aldehyde oxidase, met | RNAs | Human | Diffrenetially expressed in HCV and HBV associated HCC v/s non-tumor | Diagnostic | HCV and HBV associated HCC v/s non-tumor | p < 0.01 | Tissue | 11973655 |
| 2505 | Lactate dehydrogenase, aldehyde oxidase, nucleoside diphosphate kinase, alpha 1 catenin, beta catenin, transforming protein rho B, IgG, IgGK, IgG3, IgG1, IgG1K, IgA1, IgHA, IgG1-Fc, Collagen - alpha 1 subunit, c-jun N-terminal kinase 2, ADP/ATP carrier protein, Progression receptor associated protei | RNAs | Human | Diffrenetially expressed in cirrhotic v/s non-cirrhotic | Diagnostic | cirrhotic v/s non-cirrhotic | p < 0.01 | Tissue | 11973655 |
| 2506 | Zinc finger protein, integrin alpha 6, hepatoma derived growth factor, TGF beta induced, Macrophage inhibitory cytokine 1, lymphocyte antigen, aldehyde oxidase, c-myc purine binding transcription factor puf, plasminogen, vitronectin, hemoglobin alpha subunit, cytosolic superoxide dismutase, methylen | RNAs | Human | Diffrenetially expressed in moderately differentiated HCC v/s poorly differentiated HCC | Diagnostic | moderately differentiated HCC v/s poorly differentiated HCC | p < 0.01 | Tissue | 11973655 |
| 2507 | SGCE | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
| 2508 | PEG10 | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
| 2509 | CCL20, S100P, PEG10, SGCE, XAGE-1, COL4A1, ZNF83, and TM4SF1 | RNAs | Human | Upregulated in HCC than non-tumor (with > 3 fold change) | Diagnostic | HCC v/s non-tumor | p < 0.05 | Cell line, Tissue | 19171046 |
| 2522 | BIC, CPNE1, RBPMS, RFC4, RPSA, TOP2A | RNAs | Human | Upregulated in dedifferentiated HCC (with fold change > 2.6) | Diagnostic | moderately and well differentiated HCC v/s low-differentiated HCC | FDR < 2%. | Tissue | 18820673 |